<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Comprehensive genomic profiles of small cell lung cancer</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Reinhard</forename><surname>Bu ¨ttner</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Department of Pathology</orgName>
								<orgName type="institution">University Hospital Cologne</orgName>
								<address>
									<postCode>50937</postCode>
									<settlement>Cologne</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Stefan</forename><forename type="middle">A</forename><surname>Haas</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Department of Pathology</orgName>
								<orgName type="institution">University Hospital Cologne</orgName>
								<address>
									<postCode>50937</postCode>
									<settlement>Cologne</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Elisabeth</forename><surname>Brambilla</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Martin</forename><surname>Peifer</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Translational Genomics</orgName>
								<orgName type="department" key="dep2">Center of Integrated Oncology Cologne-Bonn</orgName>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Medical Faculty</orgName>
								<orgName type="institution">University of Cologne</orgName>
								<address>
									<postCode>50931</postCode>
									<settlement>Cologne</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Julien</forename><surname>Sage</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Departments of Pediatrics and Genetics</orgName>
								<orgName type="institution">Stanford University</orgName>
								<address>
									<postCode>94305</postCode>
									<settlement>Stanford</settlement>
									<region>California</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Roman</forename><forename type="middle">K</forename><surname>Thomas</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Translational Genomics</orgName>
								<orgName type="department" key="dep2">Center of Integrated Oncology Cologne-Bonn</orgName>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Medical Faculty</orgName>
								<orgName type="institution">University of Cologne</orgName>
								<address>
									<postCode>50931</postCode>
									<settlement>Cologne</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department">Department of Pathology</orgName>
								<orgName type="institution">University Hospital Cologne</orgName>
								<address>
									<postCode>50937</postCode>
									<settlement>Cologne</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff3">
								<orgName type="department">Department of Pathology and Center for Cancer Genome Discovery</orgName>
								<orgName type="institution">University of Ulsan College of Medicine</orgName>
								<address>
									<addrLine>Asan Medical Center 88, Olympic-ro 43-gil, Songpa-gu</addrLine>
									<postCode>138-736</postCode>
									<settlement>Seoul</settlement>
									<country key="KR">Korea</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff5">
								<orgName type="department" key="dep1">Department of Pathology</orgName>
								<orgName type="department" key="dep2">College of Medicine</orgName>
								<orgName type="institution">Hanyang University</orgName>
								<address>
									<addrLine>Seongdong-gu</addrLine>
									<postCode>222, 133-791</postCode>
									<settlement>Wangsimniro, Seoul</settlement>
									<country key="KR">Korea</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff6">
								<orgName type="laboratory">Terry Fox laboratory</orgName>
								<orgName type="institution">Vancouver General Hospital</orgName>
								<address>
									<postCode>V5Z 1L3</postCode>
									<settlement>Vancouver</settlement>
									<region>British Columbia</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff7">
								<orgName type="laboratory">European Molecular Biology Laboratory, Genome Biology Unit</orgName>
								<address>
									<postCode>69117</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff8">
								<orgName type="department" key="dep1">Institute of Pathology</orgName>
								<orgName type="department" key="dep2">Center of Integrated Oncology Cologne-Bonn</orgName>
								<orgName type="institution">University Hospital of Bonn</orgName>
								<address>
									<postCode>53127</postCode>
									<settlement>Bonn</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff9">
								<orgName type="department">Center for Cancer Genome Discovery</orgName>
								<orgName type="institution">University of Ulsan College of Medicine</orgName>
								<address>
									<addrLine>Asan Medical Center 88, Olympic-ro 43-gil, Songpa-gu</addrLine>
									<postCode>138-736</postCode>
									<settlement>Seoul</settlement>
									<country key="KR">Korea</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff10">
								<orgName type="department" key="dep1">Department of Genetics</orgName>
								<orgName type="department" key="dep2">Lineberger Comprehensive Cancer Center</orgName>
								<orgName type="institution">The University of North Carolina at Chapel Hill</orgName>
								<address>
									<postCode>27599-7295</postCode>
									<region>North Carolina</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff11">
								<orgName type="department">Cancer Center School of Medicine</orgName>
								<orgName type="institution" key="instit1">UNC Lineberger Comprehensive</orgName>
								<orgName type="institution" key="instit2">University of North Carolina at Chapel Hill</orgName>
								<address>
									<postCode>27599-7295</postCode>
									<region>North Carolina</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff12">
								<orgName type="department">Institute of Experimental Gene Therapy and Cancer Research</orgName>
								<orgName type="institution">Rostock University Medical Center</orgName>
								<address>
									<postCode>18057</postCode>
									<settlement>Rostock</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff13">
								<orgName type="department" key="dep1">Department I of Internal Medicine</orgName>
								<orgName type="department" key="dep2">Center of Integrated Oncology Cologne-Bonn</orgName>
								<orgName type="department" key="dep3">14 Department of Internal Medicine</orgName>
								<orgName type="institution">University Hospital Cologne</orgName>
								<address>
									<postCode>50937</postCode>
									<settlement>Cologne</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff14">
								<orgName type="institution">University Hospital of Cologne</orgName>
								<address>
									<postCode>50931</postCode>
									<settlement>Cologne</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff15">
								<orgName type="department">Cologne Center for Genomics (CCG)</orgName>
								<orgName type="institution">University of Cologne</orgName>
								<address>
									<postCode>50931</postCode>
									<settlement>Cologne</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff16">
								<orgName type="department">Institute of Human Genetics</orgName>
								<orgName type="institution">University Hospital Cologne</orgName>
								<address>
									<postCode>50931</postCode>
									<settlement>Cologne</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff17">
								<orgName type="department">Division of Genome Biology</orgName>
								<orgName type="institution">National Cancer Center Research Institute</orgName>
								<address>
									<addrLine>Chuo-ku</addrLine>
									<postCode>1040045</postCode>
									<settlement>Tokyo</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff18">
								<orgName type="department" key="dep1">Genomics and Epigenomics of Cancer Prediction Program</orgName>
								<orgName type="department" key="dep2">Institute of Predictive and Personalized Medicine of Cancer (IMPPC)</orgName>
								<address>
									<postCode>08916</postCode>
									<settlement>Barcelona</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff19">
								<orgName type="department">Department of Pathology and Clinical Laboratories</orgName>
								<orgName type="institution">National Cancer Center Hospital Chuo-ku</orgName>
								<address>
									<postCode>1040045</postCode>
									<settlement>Tokyo</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff20">
								<orgName type="department" key="dep1">Department of Pathology</orgName>
								<orgName type="department" key="dep2">Faculty of Medicine</orgName>
								<orgName type="institution">University of Tsukuba</orgName>
								<address>
									<postCode>305-8575</postCode>
									<settlement>Ibaraki</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff21">
								<orgName type="institution">Thoraxklinik at University Hospital Heidelberg</orgName>
								<address>
									<addrLine>Amalienstrasse 5</addrLine>
									<postCode>69126</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff22">
								<orgName type="department">Member of German Center for Lung Research (DZL)</orgName>
								<orgName type="institution">Translational Lung Research Center Heidelberg (TLRC-H)</orgName>
								<address>
									<addrLine>Amalienstrasse 5</addrLine>
									<postCode>69126</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff23">
								<orgName type="department">Institute of Pathology</orgName>
								<orgName type="institution">University of Heidelberg</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 220</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff24">
								<orgName type="department">Institute of Pathology</orgName>
								<orgName type="institution" key="instit1">Jena University Hospital</orgName>
								<orgName type="institution" key="instit2">Friedrich-Schiller-University</orgName>
								<address>
									<postCode>07743</postCode>
									<settlement>Jena</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff25">
								<orgName type="department">Institute of Surgical Pathology</orgName>
								<orgName type="institution">University Hospital Zu ¨rich</orgName>
								<address>
									<addrLine>8091 Zu ¨rich</addrLine>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff26">
								<orgName type="department">Department of Oncology</orgName>
								<orgName type="institution" key="instit1">University of Ulsan College of Medicine</orgName>
								<orgName type="institution" key="instit2">Asan Medical Center</orgName>
								<address>
									<addrLine>88, Olympic-ro 43-gil, Songpa-gu</addrLine>
									<postCode>138-736</postCode>
									<settlement>Seoul</settlement>
									<country key="KR">Korea</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff27">
								<orgName type="department">Department of Thoracic and Cardiovascular Surgery</orgName>
								<orgName type="institution" key="instit1">University of Ulsan College of Medicine</orgName>
								<orgName type="institution" key="instit2">Asan Medical Center</orgName>
								<address>
									<addrLine>Olympic-ro 43-gil, Songpa-gu</addrLine>
									<postCode>88, 138-736</postCode>
									<settlement>Seoul</settlement>
									<country key="KR">Korea</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff28">
								<orgName type="institution">Thoracic Program</orgName>
								<address>
									<addrLine>Vanderbilt-Ingram Cancer Center PRB 640, 2220 Pierce Avenue</addrLine>
									<postCode>37232</postCode>
									<settlement>Nashville</settlement>
									<region>Tennessee</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff29">
								<orgName type="department" key="dep1">Clinical Center of Serbia</orgName>
								<orgName type="department" key="dep2">Medical School</orgName>
								<orgName type="institution" key="instit1">University Hospital of Pulmonology</orgName>
								<orgName type="institution" key="instit2">University of Belgrade</orgName>
								<address>
									<postCode>11000</postCode>
									<settlement>Belgrade</settlement>
									<country key="RS">Serbia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff30">
								<orgName type="department">Department of Surgery</orgName>
								<orgName type="institution">St. Vincent&apos;s Hospital</orgName>
								<address>
									<addrLine>Peter MacCallum Cancer Centre</addrLine>
									<postCode>3065</postCode>
									<settlement>Melbourne, Victoria</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff31">
								<orgName type="department">Department of Pathology</orgName>
								<orgName type="institution">St. Vincent&apos;s Hospital</orgName>
								<address>
									<addrLine>Peter MacCallum Cancer Centre</addrLine>
									<postCode>3065</postCode>
									<settlement>Melbourne, Victoria</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff32">
								<orgName type="department">Department of Haematology and Medical Oncology</orgName>
								<address>
									<addrLine>Peter MacCallum Cancer Centre</addrLine>
									<postCode>3065</postCode>
									<settlement>Melbourne, Victoria</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff33">
								<orgName type="department" key="dep1">Comprehensive Pneumology Center Munich</orgName>
								<orgName type="department" key="dep2">German Center for Lung Research (DZL)</orgName>
								<orgName type="institution">Asklepios Biobank fu ¨r Lungenerkrankungen</orgName>
								<address>
									<addrLine>Asklepios Fachkliniken Mu ¨nchen-Gauting 82131</addrLine>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff34">
								<orgName type="laboratory">Laboratory of Oncology</orgName>
								<orgName type="institution">IRCCS Casa Sollievo della Sofferenza</orgName>
								<address>
									<addrLine>Viale Cappuccini</addrLine>
									<postCode>71013</postCode>
									<settlement>San Giovanni, Rotondo</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff35">
								<orgName type="department" key="dep1">Department of Molecular and Clinical Cancer Medicine</orgName>
								<orgName type="department" key="dep2">Institute of Translational Medicine</orgName>
								<orgName type="institution" key="instit1">Roy Castle Lung Cancer Research Programme</orgName>
								<orgName type="institution" key="instit2">The University of Liverpool Cancer Research Centre</orgName>
								<address>
									<addrLine>200 London Road</addrLine>
									<postCode>L69 3GA</postCode>
									<settlement>Liverpool</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff36">
								<orgName type="department" key="dep1">School of Medicine</orgName>
								<orgName type="department" key="dep2">Department for Respiratory Diseases Jordanovac</orgName>
								<orgName type="institution" key="instit1">University of Zagreb</orgName>
								<orgName type="institution" key="instit2">University Hospital Center Zagreb</orgName>
								<address>
									<postCode>10000</postCode>
									<settlement>Zagreb</settlement>
									<country key="HR">Croatia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff37">
								<orgName type="laboratory">Laboratory for Translational Medicine</orgName>
								<orgName type="institution">Rudjer Boskovic Institute</orgName>
								<address>
									<postCode>10000</postCode>
									<settlement>Zagreb</settlement>
									<country key="HR">Croatia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff38">
								<orgName type="department">Charite ´Comprehensive Cancer Center</orgName>
								<address>
									<postCode>10115</postCode>
									<settlement>Charite ´Campus Mitte</settlement>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Comprehensive genomic profiles of small cell lung cancer</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">B06D56B530F9191469F064AC30A7D94F</idno>
					<idno type="DOI">10.1038/nature14664</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:10+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract/>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>We have sequenced the genomes of 110 small cell lung cancers (SCLC), one of the deadliest human cancers.</s><s>In nearly all the tumours analysed we found bi-allelic inactivation of TP53 and RB1, sometimes by complex genomic rearrangements.</s><s>Two tumours with wild-type RB1 had evidence of chromothripsis leading to overexpression of cyclin D1 (encoded by the CCND1 gene), revealing an alternative mechanism of Rb1 deregulation.</s><s>Thus, loss of the tumour suppressors TP53 and RB1 is obligatory in SCLC.</s><s>We discovered somatic genomic rearrangements of TP73 that create an oncogenic version of this gene, TP73Dex2/3.</s><s>In rare cases, SCLC tumours exhibited kinase gene mutations, providing a possible therapeutic opportunity for individual patients.</s><s>Finally, we observed inactivating mutations in NOTCH family genes in 25% of human SCLC.</s><s>Accordingly, activation of Notch signalling in a pre-clinical SCLC mouse model strikingly reduced the number of tumours and extended the survival of the mutant mice.</s><s>Furthermore, neuroendocrine gene expression was abrogated by Notch activity in SCLC cells.</s><s>This first comprehensive study of somatic genome alterations in SCLC uncovers several key biological processes and identifies candidate therapeutic targets in this highly lethal form of cancer.</s></p><p><s>Small cell lung cancer (SCLC) accounts for approximately 15% of all lung cancers, arises in heavy smokers, and the tumour cells express neuroendocrine markers.</s><s>Although chemotherapy is initially effective in the treatment of SCLC, recurrence arises rapidly in the vast majority of cases, usually killing the patient within only a few months <ref type="bibr">1</ref> .</s><s>SCLC is rarely treated by surgery and few specimens are available for genomic characterization.</s><s>Previous studies applying mostly exome sequencing in a limited number of tumour specimens have revealed only a few recurrently mutated genes 2,3 .</s></p><p><s>We hypothesized that complex genomic rearrangements, which are undetectable by exome sequencing, might further contribute to the pathogenesis of SCLC and thus performed whole-genome sequencing of 110 human SCLC specimens (Supplementary Tables <ref type="table">1-4</ref>).</s><s>One of the hallmarks of SCLC is the high frequency of mutations in TP53 and RB1 (refs 2-7).</s><s>As mice lacking Trp53 and Rb1 in the lung develop SCLC <ref type="bibr" target="#b3">8,</ref><ref type="bibr" target="#b4">9</ref> , we also sequenced 8 of these murine SCLC tumours in order to identify mutations that may promote SCLC development following loss of Trp53 and Rb1 and that may overlap with such accessory genes in human SCLC <ref type="bibr" target="#b5">10</ref> (Supplementary Table <ref type="table">5</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Samples and clinical data</head><p><s>We collected 152 fresh-frozen clinical tumour specimens obtained from patients diagnosed with stage I-IV SCLC under institutional review board approval (Supplementary Table <ref type="table">1</ref> and Extended Data Fig. <ref type="figure">1</ref>).</s><s>The tumour samples were enriched for earlier stages and consisted of primary lung (n 5 148) and metastatic tumours (n 5 4) obtained by surgical resection (n 5 132), biopsy (n 5 4), pleural effusion (n 5 1) or through autopsy (n 5 15).</s><s>We performed whole-genome sequencing on 110 of these tumours and their matched normal DNA.</s><s>A total of 42 cases were excluded from the analysis because of insufficient quality or amount of DNA.</s><s>Most of these 110 tumours were treatment-naive, with only five cases obtained at the time of relapse.</s><s>We analysed transcriptome sequencing data in 71 of the 110 specimens that had undergone genome sequencing and in 10 additional specimens.</s><s>Finally, 103 of the 110 genome-sequenced specimens and 39 additional specimens were analysed by Affymetrix 6.0 SNP arrays (Supplementary Table <ref type="table">1</ref> and Extended Data Fig. <ref type="figure">1</ref>).</s><s>Eight tumour samples from preclinical SCLC mouse models were analysed by whole-exome sequencing (n 5 6) or whole-genome sequencing (n 5 2) (Supplementary Table <ref type="table">5</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Recurrent somatic alterations in SCLC</head><p><s>SCLC genomes exhibited extremely high mutation rates 2,3 of 8.62 nonsynonomous mutations per million base pairs (Mb).</s><s>C:G.A:T transversions were found in 28% of all mutations on average, a pattern indicative of heavy smoking (Fig. <ref type="figure">1a</ref> and Supplementary Tables <ref type="table">2  and 3</ref>).</s><s>The smoking history or clinical stage of the tumours did not correlate with the type and number of mutations (Extended Data Fig. <ref type="figure" target="#fig_1">2</ref>).</s><s>The median tumour content was 84% (Extended Data Fig. <ref type="figure" target="#fig_2">3a</ref> and Supplementary Table <ref type="table">2</ref>).</s><s>By contrast, murine SCLC tumours showed a low number of somatic alterations (on average 28.5 protein-altering mutations per sample on average) <ref type="bibr" target="#b5">10</ref> (Supplementary Table <ref type="table">5</ref>).</s></p><p><s>In order to assess the amount of genetic heterogeneity of SCLC, we developed a subclonality score, which can be interpreted as the probability that an arbitrary point mutation in a randomly selected cancer cell is subclonal throughout the entire tumour (Methods).</s><s>A reliable reconstruction of the subclonal architecture was possible in 55 of the cases (Extended Data Fig. <ref type="figure" target="#fig_2">3b</ref>).</s><s>A comparison to lung adenocarcinoma <ref type="bibr" target="#b6">11</ref> indicated a threefold lower subclonal diversity in SCLC (P 5 0.00023, Extended Data Fig. <ref type="figure" target="#fig_2">3b</ref>), pointing to pronounced differences in the evolution of SCLC and lung adenocarcinoma <ref type="bibr" target="#b7">12,</ref><ref type="bibr" target="#b8">13</ref> .</s><s>In contrast to adenocarcinomas, the level of heterogeneity in SCLC did not correlate with clinical stage (Extended Data Fig. <ref type="figure" target="#fig_1">2b</ref>).</s></p><p><s>We applied several analytical filters in order to identify mutations with a probable relevance in SCLC biology in the context of the high load of background mutations 2 (Extended Data Fig. <ref type="figure">1</ref>, Supplementary Table <ref type="table">6</ref> and Methods).</s><s>They include (I) analyses of significance determined by a comparison of observed and expected mutation rates followed by a correction for expressed genes, (II) a survey of regional clustering of mutations that may indicate mutational targeting of functionally enriched areas in tumour suppressors or protooncogenes, (III) determination of genes that are enriched for likely damaging mutations, (IV) a comparison with genes whose biological relevance has been established in SCLC mouse models, and (V) a listing of genes with a likely therapeutic relevance or that are otherwise G2015 Macmillan Publishers Limited.</s><s>All rights reserved frequently affected by genetic alterations in human cancers (that is, genes in the Cancer Gene Census <ref type="bibr" target="#b9">14</ref> and COSMIC 15 database).</s></p><p><s>Among the significantly mutated genes (I), (q-values , 0.05, Methods) were TP53 and RB1 (refs 4-7), KIAA1211 and COL22A1, as well as RGS7 and FPR1, both of which are involved in G-proteincoupled receptor signalling (Fig. <ref type="figure">1a</ref>).</s></p><p><s>Locally clustered mutations (II) are indicative of functional selection (P , 0.05, Supplementary Table <ref type="table">6</ref>, Methods) 2, <ref type="bibr" target="#b11">16</ref> .</s><s>Of all genes, Fig. <ref type="figure">1a</ref> lists those alterations that occurred in more than 8% of the samples, were otherwise affected by recurrent genomic rearrangements (Supplementary Table <ref type="table">4</ref>), or were mutated in Trp53 2/2 , Rb1 2/2 or Trp53 2/2 , Rb1 2/2 , Rbl2 2/2 SCLC tumours arising in mice <ref type="bibr" target="#b3">8,</ref><ref type="bibr" target="#b4">9</ref> (Supplementary Table <ref type="table">5</ref>).</s><s>Confirming previous results and our analytical strategy, the histone acetyltransferase genes CREBBP and EP300 exhibited significantly clustered mutations and recurrent inactivating translocations (Fig. <ref type="figure">1a</ref> and Extended Data Fig. <ref type="figure" target="#fig_2">3c</ref>) 2,3 .</s><s>Furthermore, significant mutation clustering occurred in genes with functional roles in the centrosome (ASPM, ALMS1 and PDE4DIP), in the RNA-regulating gene XRN1 and the tetraspanin gene PTGFRN; the latter was also mutated in murine SCLC (Extended Data Fig. <ref type="figure" target="#fig_2">3c</ref>).</s><s>The TP53 homologue TP73, which was also affected by recurrent somatic rearrangements (Fig. <ref type="figure">1a</ref>), also showed clustered mutations.</s></p><p><s>In the group of significantly damaged genes (III) we also found TP53, RB1, CREBBP and COL22A1, further highlighting their likely biological relevance in SCLC.</s><s>Additional inactivating mutations occurred in FMN2 and NOTCH1 (P , 0.01).</s><s>NOTCH family genes were recurrently mutated with a pattern of frequent inactivation.</s><s>Notch3 was also mutated in a Trp53 2/2 ,Rb1 2/2 ,Rbl2 2/2 mouse tumour (Fig. <ref type="figure">1a</ref>, Supplementary Table <ref type="table">5</ref> and Methods).</s></p><p><s>Of the genes with an established role in murine SCLC (IV), we confirmed PTEN <ref type="bibr" target="#b5">10,</ref><ref type="bibr" target="#b12">17</ref> .</s><s>RBL1 and RBL2, which are closely related to RB1 (ref.</s><s>9), similarly exhibited inactivating translocations and mutations (Fig. <ref type="figure">1a</ref>, Extended Data Fig. <ref type="figure" target="#fig_2">3d</ref> and Supplementary Table <ref type="table">4</ref>).</s><s>Mice with inactivation of Trp53, Rb1 and Rbl2 develop SCLC with shorter latency than mice lacking Trp53 and Rb1 alone <ref type="bibr" target="#b4">9</ref> , thus validating RBL2 as another accessory tumour suppressor in SCLC.</s></p><p><s>Given the lack of therapeutic options in SCLC, we sought mutations that are known oncogenic drivers in other cancers and sometimes associated with response to targeted drugs (V) <ref type="bibr" target="#b9">14,</ref><ref type="bibr" target="#b10">15</ref> .</s><s>Of these, we found mutations in four tumours with a potential therapeutic implication, including mutations in BRAF <ref type="bibr" target="#b13">18</ref> , KIT <ref type="bibr" target="#b14">19,</ref><ref type="bibr" target="#b15">20</ref> and PIK3CA 21 (Extended Data Fig. <ref type="figure" target="#fig_2">3e</ref>).</s><s>Thus, genotyping of SCLC patients may reveal individual patients who might have a possible benefit from targeted therapeutic intervention.</s></p><p><s>Across these five categories, mutations in CREBBP, EP300, TP73, RBL1, RBL2 and NOTCH family genes were largely mutually exclusive (Fig. <ref type="figure">1a</ref>), suggesting that they may exert similar pro-tumorigenic functions in the development of SCLC.</s><s>We did not observe significant correlations of global mutational signatures (for example, predominance of C:G.A:T transversions) with the mutational status of these genes (Extended Data Fig. <ref type="figure" target="#fig_1">2b</ref>).</s><s>Furthermore, mutations in these genes were not significantly associated with the total number of mutations, overall survival or other clinical parameters (Extended Data Fig. <ref type="figure">4</ref>).</s><s>The mutation status of 22 of the most frequently mutated genes was confirmed in an independent data set (Methods and Supplementary Table 7).</s></p><p><s>By analysing somatic copy number alterations, we confirmed previously known genomic losses within 3p pointing to focal events on 3p14.3-3p14.2</s><s>(harbouring FHIT 5 ) and 3p12.3-3p12.2</s><s>(harbouring ROBO1 (ref.</s><s>22)) (Fig. <ref type="figure">1b</ref>, Extended Data Fig. <ref type="figure">5a</ref> and Supplementary Table <ref type="table">8</ref>) <ref type="bibr" target="#b0">5,</ref><ref type="bibr" target="#b17">22,</ref><ref type="bibr" target="#b18">23</ref> .</s><s>FHIT expression was also reduced in cases with focal deletions (Extended Data Fig. <ref type="figure">5b</ref>).</s><s>In addition to homozygous losses in the CDKN2A locus (Extended Data Fig. <ref type="figure">5c</ref>), amplification of the MYC family genes <ref type="bibr" target="#b0">5</ref> , MYCL1, MYCN and MYC, as well as of the 1 0 .</s><s>0 1 1 0 -1 0 1 0 -1 1 5 1 0 .</s><s>0 1 1 0 -1 0 1 0 -1 1 5 18   22   Figure 1 | Genomic alterations in small cell lung cancer.</s><s>a, Tumour samples are arranged from left to right.</s><s>Alterations of SCLC candidate genes are annotated for each sample according to the colour panel below the image.</s><s>The somatic mutation frequencies for each candidate gene are plotted on the right panel.</s><s>Mutation rates and type of base-pair substitution are displayed in the top and bottom panel, respectively.</s><s>Significant candidate genes are highlighted in bold (*corrected q-values , 0.05, {P , 0.05, {P , 0.01).</s><s>The respective level of significance is displayed as a heatmap on the right panel.</s><s>Genes that are also mutated in murine SCLC tumours are denoted with a 1 symbol.</s><s>Mutated cancer census genes of therapeutic relevance are denoted with a 1 symbol.</s><s>b, Somatic copy number alterations determined for 142 human SCLC tumours by single nucleotide polymorphism (SNP) arrays.</s><s>Significant amplifications (red) and deletions (blue) were determined for the chromosomal regions and are plotted as q-values (significance , 0.05).</s></p><formula xml:id="formula_0">TP53* † ‡ RB1* ‡ KIAA1211* COL22A1* ‡ RGS7* FPR1* EP300 † CREBBP † ‡ ASPM † ALMS1 † PDE4DIP † XRN1 † FMN2 † ‡ NOTCH1 ‡ NOTCH2 NOTCH3 § NOTCH4 TP73 † RBL1 RBL2 PTEN + KIT + PIK3CA + BRAF + PTGFRN † § I. Significance* q-value</formula><p><s>tyrosine kinase gene, FGFR1 (refs 2, 24), and IRS2 were recurrent genomic events (Fig. <ref type="figure">1b</ref>).</s><s>Focal IRS2 amplifications occurred in 2% of the cases (Extended Data Fig. <ref type="figure">5d, e</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Universal inactivation of TP53 and RB1</head><p><s>Inactivating mutations in TP53 and RB1 have been shown to affect up to 90% and up to 65% of SCLC, respectively <ref type="bibr">[2]</ref><ref type="bibr">[3]</ref><ref type="bibr">[4]</ref><ref type="bibr" target="#b0">[5]</ref><ref type="bibr" target="#b1">[6]</ref><ref type="bibr" target="#b2">[7]</ref> .</s><s>By contrast, our whole-genome sequencing analyses revealed that both genes were altered in all but two cases that exhibited signs of chromothripsis <ref type="bibr" target="#b20">25</ref> (Figs <ref type="figure" target="#fig_1">1 and 2</ref>).</s><s>TP53 and RB1 alterations were mostly inactivating (Supplementary Table <ref type="table">9</ref> and Extended Data Fig. <ref type="figure">6a</ref>).</s><s>Missense mutations in TP53 affected the functionally critical DNA binding domain, while RB1 was frequently altered by complex genomic translocations.</s><s>Many mutations in RB1 occurred at exon-intron junctions, which caused protein-damaging splice events as confirmed by transcriptome sequencing (Extended Data Fig. <ref type="figure">6b</ref>-e and Supplementary Tables <ref type="table">10  and 11</ref>).</s><s>In the 108 tumours without chromothripsis, TP53 and RB1 had bi-allelic losses in 100% and 93% of the cases, respectively.</s><s>Inactivating events included mutations, translocations, homozygous deletions, hemizygous losses, copy-neutral losses of heterozygosity (LOH) and LOH at higher ploidy (Fig. <ref type="figure" target="#fig_1">2a</ref>, Extended Data Fig. <ref type="figure">6</ref> and Supplementary Table <ref type="table">9</ref>).</s><s>Loss of CDKN2A occurred in cases with both bi-allelic inactivation of TP53 and RB1 and hemizygous loss of RB1 (Fig. <ref type="figure" target="#fig_1">2a</ref>).</s><s>Although emerging data supports a continuum model of inactivation of tumour suppressors across multiple cancers, TP53 and RB1 follow the classical discrete 'two-hit paradigm' pattern of Knudson-type tumour suppressors in SCLC <ref type="bibr" target="#b21">26,</ref><ref type="bibr" target="#b22">27</ref> .</s></p><p><s>The two tumours affected by chromothripsis displayed a similar pattern of massive genomic rearrangements between chromosomes 3 and 11 (Fig. <ref type="figure" target="#fig_1">2b</ref> and Extended Data Fig. <ref type="figure">7a</ref>), but lacked shared fusion transcripts in the transcriptome sequencing data, suggesting that a particular fusion is not a common target (Extended Data Fig. <ref type="figure">7b</ref> and Supplementary Table <ref type="table">12</ref>).</s><s>Of the genes on chromosomes 3 and 11, CCND1 (encoding cyclin D1) was retained (Fig. <ref type="figure" target="#fig_1">2b</ref> and Extended Data Fig. <ref type="figure">7a</ref>) resulting in significant CCND1 overexpression in both tumours, but not in the other SCLC specimens (Fig. <ref type="figure" target="#fig_1">2c, d</ref> and Supplementary Table <ref type="table">13</ref>).</s><s>Immunohistochemistry confirmed high expression of cyclin D1 and a lack of nuclear Rb1 (Fig. <ref type="figure" target="#fig_1">2e</ref>, Extended Data Fig. <ref type="figure">7c</ref>).</s><s>There were fewer proliferating Ki67-positive cells in these two cases.</s><s>As cyclin D1 negatively regulates Rb family proteins <ref type="bibr" target="#b23">28</ref> , these findings suggest that chromothripsis in cases with wild-type RB1 may compensate for genomic loss of RB1.</s></p><p><s>Together, our findings provide evidence for the notion that complete genomic loss of both TP53 and RB1 function is obligatory in the pathogenesis of SCLC.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Oncogenic genomic events affecting TP73</head><p><s>We analysed the genome sequencing data for the presence of clustered chromosomal breakpoints that may indicate a common biological target (Supplementary Table <ref type="table">14</ref>) <ref type="bibr" target="#b24">29</ref> and found 5 major clusters affecting RB1, as well as regions on chromosomes 1, 3 (3q26), 6 (affecting CDKAL1) and 22 (Fig. <ref type="figure" target="#fig_2">3a</ref>).</s><s>Breakpoints in chromosome 22 caused inactivating translocations of TTC28 (Extended Data Fig. <ref type="figure">8a</ref>) <ref type="bibr" target="#b25">30</ref> .</s><s>Breakpoints also clustered downstream of the L1HS retrotransposon in SCLC, further supporting a role for this element in cancer <ref type="bibr" target="#b26">31,</ref><ref type="bibr" target="#b27">32</ref> , (Extended Data Fig. <ref type="figure">8b</ref>).</s><s>Breakpoints on chromosomes 3, 6 and 22 did not result in changes of expression of the affected genes (Supplementary Table <ref type="table">10</ref>).</s></p><p><s>By contrast, genomic breakpoints affecting chromosome 1 clustered precisely in the TP73 locus in 7% of the cases (n 5 8).</s><s>To our surprise, several breakpoints were recurrently located in introns 1, 2 and 3 of TP73.</s><s>In two cases, breakpoints led to complex intrachromosomal rearrangements (Extended Data Fig. <ref type="figure">8c</ref> and Supplementary Table <ref type="table">4</ref>), while the majority of breaks caused intragenic fusions and, thus, exclusion of either exon 2, or exons 2 and 3, which were all somatic (Fig. <ref type="figure" target="#fig_2">3b</ref> and Extended Data Fig. <ref type="figure">8d</ref>).</s><s>Some rearrangements were copy-neutral events, while others occurred on the background of copy number gains (Extended Data Fig. <ref type="figure">8e</ref>).</s><s>One tumour sample revealed genomic exclusion of exon 10 (Fig. <ref type="figure" target="#fig_2">3b</ref>).</s><s>Analyses of transcriptome sequencing data confirmed that these rearrangements created the N-terminally truncated transcript variants p73Dex2 and p73Dex2/3, as well as p73Dex10 (ref.</s><s>33) (Fig. <ref type="figure" target="#fig_2">3c, d</ref> and Supplementary Table <ref type="table">11</ref>).</s><s>Genomic validation and comparative profiling of transcript variants confirmed that p73Dex2/3 were not naturally occurring splice variants in SCLC and were only found in cases with genomic rearrangements (Fig. <ref type="figure" target="#fig_2">3d</ref> and Supplementary Table <ref type="table">11</ref>).</s><s>Some tumours expressed p73Dex2, in which we failed to identify genomic rearrangements (Supplementary Table <ref type="table">11</ref>).</s></p><p><s>p73Dex2 and p73Dex2/3 lack a fully competent transactivation domain and are known tumour-derived variants of TP73 (ref.</s><s>33).</s><s>p73 with N-terminal truncations has dominant negative functions</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ARTICLE RESEARCH</head><p><s>G2015 Macmillan Publishers Limited.</s><s>All rights reserved on wild-type p73 and p53, and is a confirmed oncogene in vivo <ref type="bibr" target="#b29">34,</ref><ref type="bibr" target="#b30">35</ref> .</s><s>p73Dex10 results in an early stop codon; C-terminal truncations can similarly exert dominant-negative effects on wild-type p73 (ref.</s><s>33).</s><s>Altogether, TP73 was somatically altered by mutations and genomic rearrangements in 13% of the cases (Fig. <ref type="figure">1</ref> and Extended Data Fig. <ref type="figure">8c-e</ref>).</s><s>To our knowledge, this is the first study describing p73Dex2/3 variants to emerge as a consequence of precise genomic rearrangements.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Tumour suppressive roles of Notch in SCLC</head><p><s>In an unsupervised hierarchical clustering analysis of transcriptome sequencing data (Methods), we observed two major clusters of SCLC tumours (Fig. <ref type="figure">4a</ref> and Extended Data Fig. <ref type="figure">9a</ref>).</s><s>The majority (77%, n 5 53/69) of tumours exhibited high expression of the neuroendocrine markers CHGA (chromogranin A) 1 and GRP (gastrin releasing peptide) <ref type="bibr" target="#b0">5</ref> , had high levels of DLK1 (ref.</s><s>36), a non-canonical inhibitor of Notch signalling <ref type="bibr" target="#b31">36</ref> , and ASCL1, a lineage oncogene of neuroendo-crine cells whose expression is inhibited by active Notch signalling (Extended Data Fig. <ref type="figure">9b</ref>) <ref type="bibr" target="#b32">37,</ref><ref type="bibr" target="#b33">38</ref> .</s><s>The remaining cases (23%, n 5 16/69) also expressed SYP (synaptophysin) or NCAM1 (CD56), thus confirming that all tumours were of the typical SCLC subtype 1 (Extended Data Fig. <ref type="figure">9c</ref>).</s><s>Furthermore, no significant difference in the distribution of the major known SCLC mutations (for example, TP53, RB1 or CREBBP) existed between the two transcriptional subtypes (Extended Data Fig. <ref type="figure">9a</ref>).</s><s>Thus, although all SCLC tumours shared the most frequent mutations as well as key neuroendocrine markers, the majority had a gene expression pattern suggestive of low Notch pathway activity (high levels of ASCL1 and DLK1).</s></p><p><s>Mutations affected NOTCH family genes in both human and murine SCLC (Fig. <ref type="figure">1a</ref> and Supplementary Table <ref type="table">5</ref>).</s><s>The mutations did not cluster significantly in any individual domains, but frequent damaging mutations occurred in the extracellular domain (Fig. <ref type="figure">4b</ref> and Extended Data Fig. <ref type="figure">10a</ref>), suggesting that NOTCH may be a tumour suppressor in SCLC.</s><s>Overall, the NOTCH family was affected by genomic alterations in 25% of human SCLC (Fig. <ref type="figure">1</ref>).</s></p><p><s>Based on these observations and emerging evidence that activation of Notch signalling may inhibit the expansion of neuroendocrine tumour cells <ref type="bibr" target="#b34">39,</ref><ref type="bibr" target="#b35">40</ref> , we examined the consequences of Notch pathway activation in Trp53;Rb1;Rbl2 conditional triple-knockout (TKO) mice <ref type="bibr" target="#b4">9</ref> .</s><s>We crossed Rosa26 Lox-stop-Lox-Notch2ICD (LSL-N2ICD) mice that conditionally express an activated form of Notch2 (Notch2 intracellular domain, N2ICD) to TKO mice and found a significant reduction in the number of tumours that arose in the presence of N2ICD (P , 0.001; Fig. <ref type="figure">4c</ref>).</s><s>Similar results were obtained upon activation of Notch1, reflecting a general inhibition of SCLC initiation by active Notch signalling (Extended Data Fig. <ref type="figure">10b</ref>).</s><s>The recombination efficiency of an innocuous inducible reporter allele (Rosa26 mT/mG ) by Cre was much greater than that of the N2ICD allele, providing further support for a strong negative selection against active Notch signalling during SCLC development (Extended Data Fig. <ref type="figure">10c-e</ref>).</s><s>Importantly, the inhibitory effects of Notch observed in the early stages of tumorigenesis correlated with a prolongation of survival of the mutant mice expressing N2ICD (Fig. <ref type="figure">4d</ref>).</s><s>Similarly, ectopic expression of N1ICD in both mouse and human SCLC cell lines significantly inhibited their growth (Fig. <ref type="figure">4e</ref> and Extended Data Fig. <ref type="figure">10f</ref>).</s></p><p><s>SCLC tumours in TKO mice showed typical patterns of neuroendocrine differentiation with high expression of synaptophysin and Ascl1.</s><s>Consistent with the notion that Notch regulates neuroendocrine differentiation in SCLC, overexpression of N2ICD resulted in the upregulation of Hes1 and abrogated expression of neuroendocrine markers (Extended Data Fig. <ref type="figure">10g</ref>).</s><s>Similarly, N1ICD induced upregulation of Notch targets (for example, Hes1, Hey1, Hey2) in murine SCLC cells (Fig. <ref type="figure">4f</ref>, Extended Data Fig. <ref type="figure">10h</ref> and Supplementary Table <ref type="table">15</ref>), as well as gene expression signatures consistent with cell cycle inhibition (Extended Data Fig. <ref type="figure">10i</ref>).</s><s>Ectopic expression of N1ICD inhibited cell cycle progression in murine and human SCLC cell lines (Extended Data Fig. <ref type="figure">10j, k</ref>).</s><s>This cell cycle inhibition is reminiscent of what has been seen in other contexts where Notch activation acts as a tumour suppressor <ref type="bibr" target="#b36">41,</ref><ref type="bibr" target="#b37">42</ref> .</s></p><p><s>Altogether, our analyses involving genome and transcriptome sequencing of human and murine SCLC tumours, as well as studies in genetically manipulated mice, identify and validate Notch as a tumour suppressor and master regulator of neuroendocrine differentiation in SCLC.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>Here we provide a comprehensive analysis of somatic genome alterations in SCLC, identifying many novel candidate genes, some of which may have therapeutic implications.</s><s>Such alterations with immediate therapeutic consequences are rare but present in SCLC (for example, in BRAF or KIT), suggesting that individual patients may benefit from genotyping and subsequent targeted kinase inhibitor therapy.</s><s>We further discovered recurrent expression of p73Dex2/3 in SCLC and</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESEARCH ARTICLE</head><p><s>G2015 Macmillan Publishers Limited.</s><s>All rights reserved established a genetic mechanistic basis for this oncogenic variant.</s></p><p><s>TP73Dex2/3 has recently been demonstrated to function as an oncogene <ref type="bibr" target="#b29">34,</ref><ref type="bibr" target="#b30">35</ref> and therapeutic options were identified to restrict p73dependent tumour growth in vivo, including in Trp53-deficient tumours <ref type="bibr" target="#b30">35</ref> .</s><s>Given the frequent occurrence of genomic TP73 alterations in SCLC, such approaches may potentially be promising in SCLC tumours.</s><s>Our results furthermore provide proof for universal bi-allelic inactivation of TP53 and RB1, thereby establishing these two genes as obligatory tumour suppressors in SCLC.</s></p><p><s>Our genomic analyses also identified NOTCH family genes as tumour suppressors and master regulators of neuroendocrine differentiation in SCLC, and we validated this finding in vivo in a pre-clinical mouse model of this disease.</s><s>Our observations may thus provide an initial link between Notch and the neuroendocrine phenotype in SCLC.</s><s>In contrast to the involvement of TP73 and NOTCH family genes (Fig. <ref type="figure">5</ref>), the functional role of most of the other newly discovered genes (for example, KIAA1211, COL22A1, ASPM, PDE4DIP or PTGFRN) is much less clear.</s><s>Although our analytical filters support their involvement in the tumour pathogenesis, functional experiments will be required to clarify their biological role.</s></p><p><s>In summary, we have provided the first, to our knowledge, comprehensive genomic analysis of SCLC, implicating several previously unknown genes and biological processes (Fig. <ref type="figure">5</ref>) in the pathogenesis of this disease as possible targets for more efficacious targeted therapeutic intervention against this deadly cancer.</s></p><p><s>Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ARTICLE RESEARCH</head><p><s>G2015 Macmillan Publishers Limited.</s><s>All rights reserved</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>METHODS</head><p><s>Human lung tumour specimens.</s><s>The institutional review board of the University of Cologne approved this study.</s><s>We collected and analysed freshfrozen tumour samples of 152 SCLC patients, which were provided by multiple collaborating institutions as fresh-frozen tissue specimen, frozen sections or as genomic DNA extracted from fresh-frozen material (Extended Data Fig. <ref type="figure">1</ref>).</s><s>Human tumour samples were obtained from patients under IRB-approved protocols following written informed consent.</s><s>The fresh-frozen SCLC samples were primary tumours diagnosed as stage I-IV tumours, and snap-frozen after tissue sampling.</s><s>All tumour samples were pathologically assessed to have a purity of at least 60% and no extensive signs of necrosis.</s><s>Additionally, these tumour samples were reviewed by at least two independent expert pathologists and the diagnosis of SCLC was histomorphologically confirmed by H&amp;E staining and immunohistochemistry for chromogranin A, synaptophysin, CD56 and Ki67.</s><s>Matching normal material was provided in the form of EDTA-anticoagulated blood or adjacent non-tumorigenic lung tissue (Supplementary Table <ref type="table">1</ref>).</s><s>The matched normal tissue was confirmed to be free of tumour contaminants by pathological assessment.</s><s>Furthermore, tumour and matching normal material were confirmed to be acquired from the same patient by short tandem repeat (STR) analysis conducted at the Institute of Legal Medicine at the University of Cologne (Germany), or confirmed by subsequent SNP 6.0 array and sequencing analyses.</s><s>Patient material was stored at 280 uC.</s></p><p><s>Whole-genome sequencing was performed on 110 SCLC fresh-frozen tumour samples and matched normal material.</s><s>Additionally, we analysed RNA-seq data of 81 SCLC primary tumours (Extended Data Fig. <ref type="figure">1</ref> and Supplementary Table <ref type="table">1</ref>), among which 20 cases were previously published 2,43 .</s><s>Furthermore, we studied the copy-number alterations of a total of 142 fresh-frozen tumour specimen by Affymetrix SNP 6.0, among which 74 cases were described before <ref type="bibr" target="#b48">44</ref> .</s></p><p><s>Clinical correlation studies were performed with the study cohort of 110 SCLC patients considering age of diagnosis, gender, tumour stage, surgery, treatment with chemotherapeutics, smoking status, smoking history and overall survival (Extended Data Figs 2 and 4 and Supplementary Table <ref type="table">1</ref>).</s><s>The median follow-up time for this cohort of 110 SCLC patients was 69 months, and 31% of the patients were alive at the time of last follow-up (Extended Data Fig. <ref type="figure" target="#fig_1">2a</ref> and Supplementary Table <ref type="table">1</ref>).</s><s>Smoking status was available for 88% (n 5 97) of the patients; 63% (n 5 69) reported a smoking history amounting to a median of 45 pack-years.</s><s>Patients with a known smoking history were further subcategorized to heavy smokers (.30 pack-years), average smokers (10-30 pack-years) and light/never smokers (,10 pack-years).</s></p><p><s>Primary findings on somatic mutations were further studied in a second independent cohort consisting of 112 SCLC cases.</s><s>This validation cohort refers to the exome sequencing data of 28 fresh-frozen SCLC primary tumours and 9 SCLC cell lines 2,3 which were re-analysed in this present study (Supplementary Table <ref type="table">7</ref>).</s><s>Additionally, we performed targeted sequencing on 8 fresh-frozen and 67 formalin fixed paraffin embedded (FFPE) samples from SCLC patients (Supplementary Table <ref type="table">1</ref>).</s><s>Mouse SCLC models and tumour samples.</s><s>Mice were maintained according to practices prescribed by the NIH (Bethesda, MD) at Stanford's Research Animal Facility, accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care (AAALAC).</s><s>The Trp53;Rb1 double-knockout (DKO) and the Trp53;Rb1;Rbl2 triple-knockout (TKO) mouse models for SCLC have been previously described <ref type="bibr" target="#b3">8,</ref><ref type="bibr" target="#b4">9</ref> .</s><s>Mice were bred onto a mixed genetic background composed of C57BL/6, 129/SvJ and 129/SvOla.</s><s>SCLC tumours were induced in 8-week-old mice by intratracheal instillation with 4 3 10 7 plaque-forming units (p.f.u.) of adenovirus expressing the Cre recombinase (Ad-Cre, Baylor College of Medicine, Houston, TX).</s></p><p><s>Whole-genome and whole-exome sequencing was performed on 8 murine SCLC tumours isolated from DKO and TKO mice.</s><s>Primary tumours and metastases were dissected, snap-frozen, and stored at 280 uC.</s><s>The material was pathologically confirmed to have a tumour content of at least 90%.</s><s>The respective tail tissue was similarly processed and served as a normal reference for 6 tumour samples (Supplementary Table <ref type="table">5</ref>).</s><s>Average mutation rates were calculated for cases with tumour-normal pairs (n 5 6).</s></p><p><s>SCLC tumours expressing the activated intracellular domain (ICD) of Notch1 (Notch1 ICD, N1ICD) and Notch2 (Notch2 ICD, N2ICD) were analysed in mouse models.</s><s>Rosa26 Lox-stop-Lox-Notch1ICD (LSL-N1ICD) or Rosa26 Lox-stop-Lox-Notch2ICD (LSL-N2ICD) mice were obtained from Spyros Artavanis-Tsakonas and Exelixis.</s><s>These mice are similar to recently published Rosa26 1/LSL-Notch3ICD mice <ref type="bibr" target="#b49">45</ref> .</s><s>Rosa26 1/LSL-N1ICD or Rosa26 1/LSL-N2ICD mice were crossed with TKO mice.</s><s>TKO or TKO;Rosa26 1/LSL-NICD mice were infected with Ad-Cre at week 8 and their survival was monitored.</s><s>The sample size was chosen based on our experience with these mouse models of cancer (a minimum of 3-5 mice usually ensures statistical significance if the phenotypes are robust).</s><s>We used both males and females in these experiments, littermates served as controls.</s><s>Tumour initiation was studied three months after Ad-Cre instillation.</s><s>The lungs were fixed and tumour burden was quantified using ImageJ software.</s><s>To control for the efficiency of deletion, we also crossed TKO mice to Rosa26 mT/mG reporter mice <ref type="bibr" target="#b50">46</ref> .</s><s>For all tumour quantifications, the investigator was blinded to the genotypes when the H&amp;E pictures were taken, and during the quantification of tumour number and area.</s><s>No samples or animals were excluded from the analyses, and no randomization was performed.</s><s>DNA and RNA extractions.</s><s>Nucleic acids were extracted from fresh-frozen tissue specimen which were processed to 15-30 sections each of 20 mm thickness at a cryostat maintaining a temperature of 220 uC (Leica).</s><s>In the case of FFPE samples, 6-10 sections of 10 mm thickness were prepared.</s></p><p><s>DNA was extracted from fresh-frozen tissues, EDTA blood, or FFPE samples using the Gentra Puregene DNA extraction kit (Qiagen) following the protocol of the manufacturer.</s><s>DNA isolates were hydrated in TE-buffer and confirmed to be of high molecular weight (.10 kb) by agarose gel electrophoresis.</s><s>Genomic DNA from fresh-frozen samples with evident signs of degradation were excluded from further sequencing studies.</s></p><p><s>For RNA extractions, tissue sections were first lysed and homogenized with the Tissue Lyzer (Qiagen).</s><s>Subsequent RNA extractions were performed with the Qiagen RNAeasy Mini Kit according to the instructions of the manufacturer.</s><s>The RNA quality was assessed at the Bioanalyzer 2100 DNA Chip 7500 (Agilent Technologies) and samples with a RNA integrity number (RIN) of over 7 were further analysed by RNA-seq.</s><s>Next-generation sequencing.</s><s>All sequencing reactions were performed on an Illumina HiSeq 2000 instrument (Illumina, San Diego, CA, USA).</s><s>Whole-genome sequencing.</s><s>Whole-genome sequencing was performed with DNA extracted from fresh-frozen tumour and normal material.</s><s>Short insert DNA libraries were prepared with the TruSeq DNA PCRfree sample preparation kit (Illumina) for paired-end sequencing at a minimum read length of 2 3 100 bp.</s><s>Human DNA libraries were sequenced with the aim to obtain a coverage of minimum 303 for both tumour and matched normal.</s><s>Murine DNA libraries of tumour and matched normal were both sequenced to a coverage of 253.</s><s>Whole-exome sequencing.</s><s>Whole-exome sequencing was performed on freshfrozen tissue specimen from mice.</s><s>The enrichment for the exome was performed with the SureSelectXT Mouse All Exon kit (Agilent) following the protocol of the manufacturer.</s><s>The exon-enriched libraries were subjected to paired-end sequencing with a read-length of 2 3 100 bp.</s><s>Both tumour and normal material was sequenced to a minimum coverage of 603.</s><s>RNA-sequencing.</s><s>RNA-sequencing (RNA-seq) was performed with RNA extracted from fresh-frozen human tumour tissue samples.</s><s>cDNA libraries were prepared from poly(A) selected RNA applying the Illumina TruSeq protocol for mRNA.</s><s>The libraries were then sequenced with a 2 3 100 bp paired-end protocol to a minimum mean coverage of 303 of the annotated transcriptome.</s><s>Targeted enrichment sequencing.</s><s>Targeted enrichment sequencing was performed on human FFPE and fresh-frozen tumour and normal specimen for the purpose of validating genome alterations in an independent cohort.</s><s>The custom probe design was constructed with SureDesign (Agilent Technologies) enriching for the exons of 22 genes of interest.</s><s>DNA libraries were prepared with the SureSelect XT reagent kit according to the manufacturer's instructions (Agilent Technologies) and sequenced with the aim to obtain a coverage of at least 2003.</s><s>Dideoxy sequencing for validation of somatic alterations.</s><s>If available, RNA-seq or exome sequencing was used to validate somatic mutations determined by genome sequencing.</s><s>Alternatively, dideoxynucleotide chain termination sequencing (Sanger sequencing) was performed to validate mutations, genomic rearrangements, and chimaeric fusion transcripts.</s><s>Primer pairs were designed to amplify the target region encompassing the somatic alteration.</s><s>The PCR reactions were performed either with genomic DNA, whole-genome amplified DNA or cDNA.</s><s>The amplified products were subjected to Sanger sequencing and the respective electropherogram was analysed with Geneious (http://www.geneious.com).</s></p><p><s>Copy number analysis by Affymetrix SNP 6.0 arrays.</s><s>Human DNA extracted from fresh-frozen tumour specimen was hybridized to Affymetrix Genome-Wide Human SNP array 6.0 following the manufacturer's instructions.</s><s>The signal intensities were processed to analyse for chromosomal gene copy number data.</s><s>Raw copy number signals and segmented copy number data were computed following the procedure described previously <ref type="bibr" target="#b19">24</ref> .</s></p><p><s>The raw, unsegmented copy number signals were used to analyse for significant copy number alterations applying the method CGARS <ref type="bibr" target="#b51">47</ref> .</s><s>Significant amplifications were determined with the upper quantiles 0.25, 0.15, 0.1, and 0.05; deletions were computed in reference to the 0.25 lower quantile.</s><s>The significance threshold was set at a q-value of 0.05 (Supplementary Table <ref type="table">8</ref>).</s></p><p><s>Data processing.</s><s>The raw sequencing reads of human and mouse samples acquired from whole-genome, whole-exome or targeted enrichment sequencing were aligned to the respective human (NCBI37/hg19) or mouse reference genome (NCBI37/mm9).</s><s>The alignment was performed with the BWA aligner 48 (version 0.6.1-r104).</s><s>Concordant read-pairs were identified as potential PCR duplicates and were subsequently masked in the alignment file.</s><s>The quality of the sequencing data was determined and is summarized in Supplementary Table <ref type="table">2</ref>.</s></p><p><s>The whole-genome sequencing data of human samples was analysed for purity and ploidy with methods previously described 2 (Extended Data Fig. <ref type="figure" target="#fig_2">3a</ref> and Supplementary Table <ref type="table">2</ref>).</s></p><p><s>Somatic mutations and copy number alterations were determined with our inhouse analysis pipeline 2,49 .</s><s>The calling of somatic mutations in human samples was further improved by filtering the identified variant against the sequencing data of more than 500 normal samples (including exome or genome sequencing data).</s><s>Additionally, an estimation of human DNA library contamination was implemented to enhance sensitivity and specificity of mutation calling.</s><s>Analysis of significantly mutated and biologically relevant genes.</s><s>The significance of recurrently mutated genes was analysed for the whole-genome sequencing data set of 110 human SCLC samples (Extended Data Fig. <ref type="figure">1a</ref>).</s></p><p><s>As previously described 2 , the analysis first estimated the background mutation rate for each gene and corrected for its expression by referring to the RNA-seq data of 81 human primary SCLC tumour specimen analysed in the present study.</s><s>The analysis included those genes which had FPKM values (fragments per kilobase of exon per million fragments mapped) of over 1 in at least 50 samples.</s><s>Following corrections for the occurrence of synonymous mutations, significantly mutated genes were determined with q-values of ,0.05 (Fig. <ref type="figure">1a</ref>, Extended Data Fig. <ref type="figure">1a (filter I</ref>) and Supplementary Table <ref type="table">6</ref>).</s></p><p><s>Mutations that cluster within a gene are defined as a mutational hotspot similar to our previously described method 2 .</s><s>Here we used an analytical derivation of the test statistics, rather than resampling.</s><s>To this end, the mutated positions are rescaled to lie within zero and one (using the protein length).</s><s>Under the null hypothesis of having no particular mutational hotspot, the rescaled mutated positions are uniformly distributed between zero and one, thus its expected value is 0.5.</s><s>We therefore chose the final statistics as sum over the modulus of the rescaled position minus 0.5.</s><s>This allows that the distribution under the null hypothesis can analytically be calculated; hence, also the P values.</s><s>The analysis was calculated for genes that were significantly mutated in at least 5% of the samples with P , 0.05 (Fig. <ref type="figure">1a</ref>, Extended Data Fig. <ref type="figure">1a</ref> (filter II) and Supplementary Table <ref type="table">6</ref>).</s><s>In order to further filter for the genes of relevance, subsequent analysis considered those genes recurrently mutated in more than 8% (n .</s><s>8) samples.</s><s>The called genes were scored for their relevance by either analysing recurrent translocations affecting these genes (Supplementary Table <ref type="table">4</ref>) or by comparison with the mouse SCLC mutation data to identify alterations in common genes (Supplementary Table <ref type="table">5</ref>).</s></p><p><s>Additionally, recurrent mutations were scored for the accumulation of clearly damaging mutations in which splice site, frameshift and nonsense mutations were considered as damaging mutations.</s><s>Here, we restricted the aforementioned significance analysis only to this class of mutations (by restricting the background mutation rate only to damaging mutations) and determined significance at P , 0.01 (Fig. <ref type="figure">1a</ref>, Extended Data Fig. <ref type="figure">1a</ref> (filter III) and Supplementary Table <ref type="table">6</ref>).</s></p><p><s>Genetic alterations were further scored for their relevance by comparison with genes that were functionally characterized in genetically engineered mouse models (GEMM) for SCLC <ref type="bibr" target="#b4">9,</ref><ref type="bibr" target="#b5">10</ref> , or by comparing somatic mutations in SCLC with mutations in other cancer types reported in the Cancer Gene Census 14 and in COSMIC (catalogue of somatic mutations in cancer) <ref type="bibr" target="#b10">15</ref> (Fig. <ref type="figure">1a</ref>, Extended Data Fig. <ref type="figure">1a</ref> (filter IV and V) and Supplementary Table <ref type="table">6</ref>).</s><s>Additionally, the sequencing data of mouse SCLC specimen was used to identify alterations in common genes.</s><s>Analysis of subclonal architecture.</s><s>To determine the subclonal architecture from genome sequencing data, we first computed the cancer cell fraction (CCF; that is, the fraction of cancer cells carrying a particular mutation) of each called somatic point mutation.</s><s>To this end, we first estimated the tumour purity, absolute copy numbers, and subclonal copy number changes using our previously described method 2 and computed for each mutation the expected allelic fraction under clonality assumption.</s><s>The quotient between the observed allelic fraction of a mutation with its corresponding expected allelic fraction then yields the CCF.</s><s>To assess the clonal and subclonal populations we next identified distinct clusters in the CCF profile and assigned each mutation to the cluster of highest probability.</s><s>In order to provide a measure for the subclonal architecture, we proposed the following score: Subclonality score~X nc i~1 w i m i X nc i~0 w i m i where i 5 0 represents the clonal population, i 5 1,…,nc the subclonal populations; Q i is the CCF of each population (thus, Q 0 &lt; 1), and m i is the number of mutations assigned to cluster i.</s><s>This subclonality score can be interpreted as the probability that a randomly selected mutation present in a single cancer cell is subclonal throughout the entire tumour.</s></p><p><s>As a low sequencing depth limits the robust identification of subclonal populations, we computed the genome-wide average contribution of a single mutated read to the CCF.</s><s>For a given tumour purity p, average ploidy p, and mean coverage c, this measure is given by: Average increase of CCF per read~2 (1{p)zpp pc</s></p><p><s>The smaller the average increase of CCF per read, the more accurately the subclonality score can be determined since more subclonal mutations can be called from the sequencing data.</s><s>In this study, the most limiting factor for assessing the subclonal diversity is the relatively low sequencing depth (353 on average).</s><s>We therefore used this measure to select the samples that are suitable for a reliable calculation of the subclonality score.</s><s>To this end, we systematically scanned from the average increase of CCF per read form large to small values and detected the point of the most prominent change in the distribution of the subclonality score (Supplementary Table <ref type="table">2</ref>).</s></p><p><s>Analysis of genomic breakpoints.</s><s>Genomic rearrangements were reconstructed from the whole-genome sequencing data of 110 human SCLC samples following the procedure as previously described 2, <ref type="bibr" target="#b53">49</ref> .</s><s>The genomic rearrangements called from each tumour sample were further filtered against a library of 110 normal genomes to thus minimize the detection of false-positive rearrangements.</s><s>Genomic breakpoints of SCLC candidate driver genes are listed in Supplementary Table <ref type="table">4</ref>.</s></p><p><s>The genomic breakpoints of all samples were mapped to their chromosomal locations and recurrent breakpoints clustering within the range of 100 kb were identified with a similar approach described previously <ref type="bibr" target="#b24">29</ref> (Supplementary Table <ref type="table">14</ref>).</s><s>Processing and analysis of RNA-seq data.</s><s>RNA-seq data was processed as previously described 2,49 to detect chimaeric transcripts and to determine the transcriptional abundance of annotated transcript variants.</s><s>In brief, paired-end RNA-seq reads were mapped to the human reference genome (NCBI37/hg19) using GSNAP.</s><s>Potential chimaeric fusion transcripts were identified by discordant read pairs and by individual reads mapping to distinct chromosomal locations.</s><s>The sequence context of rearranged transcripts was reconstructed around the identified breakpoint and the assembled fusion transcript was then aligned to the human reference genome to determine the genes involved in the fusion.</s></p><p><s>Cufflinks was used to determine the expression levels of annotated transcripts referring to unique paired-end reads which align within the expected mapping distance.</s><s>The expression is represented as FPKM values (Supplementary Table <ref type="table">10</ref>).</s><s>Transcript splicing analysis.</s><s>RNA-seq data was used to analyse for alternative splicing events of TP53, RB1 and TP73 caused by exon skipping or intron retention (Supplementary Table <ref type="table">11</ref>).</s><s>The paired-end reads were mapped to the reference genome (hg19) using STAR mapper.</s><s>In reference to the annotation of exon junctions provided from UCSC genes and RefSeq the following parameters were applied: ref 1, options:-alignIntronMin 20,-alignIntronMax 500000,-outFilterMismatchNmax 10, and-chimSegmentMin 10.</s><s>The coordinates of reads potentially crossing exon boundaries were derived from the respective ''SJ.out.tab''</s><s>file and compared to the reference annotation.</s><s>Subsequently, junction read counts were assigned to all transcripts containing the respective exon combination.</s><s>If the exon combination is novel, read counts were assigned to those transcripts sharing one of the exons contributing to the novel junction.</s><s>For subsequent analyses the transcript with the highest number of junction read counts was used as a reference.</s><s>Additionally, for exon combinations unique to alternative transcripts a representative transcript was selected based on total read counts.</s><s>The read counts of each exon junction were normalized to the reads per kilobase per million mapped reads (RPKM) per sample.</s><s>These expression values were further normalized per gene by dividing by the average expression of the exons of the reference transcript.</s><s>Potentially novel exon combinations were rejected if the average expression of the reference transcript was ,2 or if their expression were ,10% of the reference transcript expression.</s><s>Differential expression for outlier studies.</s><s>Differential gene expression analysis was performed to compare the transcriptional profile of the two chromothripsis cases (S02297 and S02353) with other non-chromothripsis SCLC cases and to thus identify outliers in the expression profile.</s><s>The expression was analysed by computing z-scores for all samples referring to the RPKM values and using the R function 'scale'; RPKM values smaller than 3 were set to 0. In order to prioritize for genes differentially expressed in the two samples S02297 and S02353, genes were ranked by their respective z-scores.</s><s>Statistical testing was performed for genes on Chr 3 and Chr 11, respectively.</s><s>The P values were then combined from the two samples using Fisher's method and corrected for multiple hypothesis testing by using the Benjamini-Hochberg approach.</s><s>Differentially</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ARTICLE RESEARCH</head><p><s>expressed genes with a P , 0.05 and q-values ,0.01 are provided in Supplementary Table <ref type="table">13</ref>.</s><s>Unsupervised expression clustering.</s><s>Unsupervised clustering was performed with RNA-seq data of 69 SCLC cases for which matching genome sequencing data was available (Fig. <ref type="figure">4a</ref> and Extended Data Fig. <ref type="figure">9a</ref>).</s><s>As expression values are approximately following log-normal distribution, we transformed raw FPKM of each transcript by log 2 (11FPKM).</s><s>The resulting expression scores were then searched for a high and low expression characteristic over the samples.</s><s>To this end, expression scores of each transcript were divided into two states using k-means clustering.</s><s>To prevent an accumulation of artificial signals, only transcripts with at least 6 samples in each state and having a state-averaged fold change larger than 3 are considered for further analysis.</s><s>A t-test is then computed between the two states of the remaining transcripts and corrected for multiple hypothesis testing using the false discovery rate framework.</s><s>Next, transcripts having a q-value smaller than 0.01 were selected.</s><s>For genes with multiple transcript variants, the transcript with the smallest q-value was chosen as representative transcript.</s><s>Then, invariant genes were removed (having a standard deviation across all samples ,2).</s><s>To improve clustering, only genes that share a similar pattern of the two states in at least 6 other genes are finally selected (using a Fisher's exact test with a significance threshold of 10 26 ).</s><s>Using the determined list of transcripts/genes, hierarchical clustering (Euclidean distance, complete linkage) was performed on the raw expression scores.</s><s>IRS2 amplification FISH assay.</s><s>A fluorescence in situ hybridization (FISH) assay was used to detect and confirm IRS2 amplifications at the chromosomal level.</s><s>We performed a signal detection approach, with two probes on chromosome 13: the reference probe is located on the centromeric region of chromosome 13 (Empire Genomics, Art.Nr.: CHR13-10-GR) and was labelled with green 5-fluorescein dUTP to produce a green signal; the target probe is located on the IRS2 locus spanning 13q33.3-34</s><s>and was labelled with biotin to produce a red signal using the CTD-2083015 BAC clone (Life Technologies, CA, USA).</s><s>As previously described <ref type="bibr" target="#b19">24</ref> , slides of FFPE and fresh-frozen samples of tumour tissues were prepared, stained and analysed at a fluorescence microscope (Zeiss, Jena, Germany) with a 633 oil immersion objective.</s><s>A non-amplified nucleus showed one red target signal for every corresponding green reference signal, with a red/ green ratio of 1:1 (Extended Data Fig. <ref type="figure">5e</ref>).</s><s>High-level amplifications were determined for at least 10 red signals.</s><s>In some cases the red signals were observed as clusters in the cells.</s><s>At least 100 nuclei per case were evaluated.</s><s>Immunohistochemistry. Immunohistochemistry was performed on human tumour FFPE samples to analyse for the protein expression of Rb, cyclin D1, p53, p14 (ARF), and p16.</s><s>The staining was performed with the BenchMark XT automated immunohistochemistry slide staining system (Roche).</s><s>The following antibodies and conditions were applied: Rb (C-15) rabbit polyclonal (Santa Cruz; FFPE retrieving conditions: 60 min at pH 6.0; dilution: 1:500; incubation: 60 min, 37 uC); Cyclin D1 clone SP4 rabbit monoclonal (Microm France; FFPE retrieving conditions: 90 min at pH 8.4; dilution: 1:200; incubation: 60 min, 37 uC); p53 clone DO7 mouse monoclonal (Dako; FFPE retrieving conditions: 60 min at pH 8.4; dilution: 1:25; incubation: 60 min, 37 uC); p14 ARF clone 4C6/4 mouse monoclonal (Cell Signaling; FFPE retrieving conditions: 60 min, water-bath 98 uC at pH 6.0; manual immunohistochemistry staining with Novolink Max polymer detection system (Leica); dilution: 1:4,000; incubation: overnight, 4 uC); p16 INK4 Ab-7 clone PO7 mouse monoclonal (Neomarkers; FFPE retrieving conditions: 60 min at pH 8.4; dilution: 1:800; incubation: 60 min, room temperature).</s></p><p><s>For immunohistochemistry on mouse tumour FFPE samples, sections were permeabilized for antigen retrieval by microwaving in a citrate-based antigen unmasking solution (Vector Laboratories).</s><s>The following antibodies were used: GFP (Invitrogen; A11122; dilution: 1:400), RFP/Tomato (Rockland Immunochemicals; 600-401-379; dilution: 1:500), Notch2 (Cell Signaling; 5732; dilution: 1:200), Hes1 (Cell Signaling; 11988; dilution: 1:200), Ascl1 (BD Biosciences; 556604; dilution: 1:200) and Synaptophysin (Neuromics; MO20000; dilution: 1:200).</s><s>Sections were developed with DAB (Vector Labs) and counterstained with haematoxylin.</s></p><p><s>Cell lines, tissue culture and transfections.</s><s>Mouse (KP1) and human (NJH29, NCI-H82 and NCI-H187) SCLC cell lines were grown in RPMI-1640 media supplemented with 10% bovine growth serum (BGS) (Fisher Scientific) and penicillin-streptomycin-glutamine (Gibco), as described before <ref type="bibr" target="#b54">50</ref> .</s><s>KP1, NJH29 were generated at Stanford.</s><s>NCI-H82 and NCI-H187 were purchased from ATCC.</s><s>These cells grow as suspension spheres or aggregates in culture.</s><s>All cell lines were maintained at 37 uC in a humidified chamber with 5% CO 2 .</s><s>All cell lines tested negative for mycoplasma infection.</s><s>For transient expression of Notch ICD, cells were trypsinized and transfected with either MigR1-IRES-GFP (Ctrl) or MigR1-Notch1-ICD-IRES-GFP (NICD) using Lipofectamine 2000 (Life Technologies).</s><s>The plasmids were gifts from W.S. Pear (University of Pennsylvania, Philadelphia).</s><s>Then 48 h after transfection, cells were trypsinized and resuspended in phosphate-buffered saline (PBS) containing 10% BGS and 1 mg ml <ref type="bibr" target="#b16">21</ref> 7-aminoactinomycin D (Life Technologies) that labels dead cells.</s><s>Live GFP 1 cells were then sorted for subsequent experiments using a BD FACSAria fluorescence-activated cell sorting (FACS) machine.</s><s>Gene expression and microarray analysis.</s><s>Gene expression and microarray analyses were performed with the mouse cell line KP1 transiently transfected with MigR1-IRES-GFP (Ctrl) or MigR1-Notch1-ICD-IRES-GFP (N1ICD).</s></p><p><s>Then 1 3 10 5 GFP 1 cells were sorted and the RNA isolated using the AllPrep DNA/RNA micro kit (Qiagen).</s><s>RNA quality assessment using the 2100 Bioanalyzer (Agilent) as well as the subsequent cDNA preparation steps for microarray analysis were performed at the Stanford Protein and Nucleic Acid (PAN) facility using the GeneChip Mouse Gene 2.0 ST Array (Affymetrix).</s><s>For gene expression analysis, the Robust Multichip Average (RMA) Express 1.0.4 program was used for background adjustment and quantile RMA normalization of the 41,345 probe sets encoding mouse genome transcripts.</s><s>Linear models for microarray data (LIMMA) was used to compare Ctrl or N1ICD samples on RMA normalized signal intensities.</s><s>Only genes with an adjusted P value of 0.05 or less were considered as significantly differentially expressed.</s><s>A total of 769 probes accounting for 760 genes were significant, and the expression levels of these genes were represented as a heatmap using the heatmap.2</s><s>function in R. The analysis was performed in triplicates.</s><s>A list of significant genes is provided in Supplementary Table <ref type="table">15</ref>.</s><s>MTT cell viability assay.</s><s>Sorted GFP 1 cells were seeded at 1 3 10 4 per well in 96well plates.</s><s>The MTT reagents (Roche) were added on days 0, 2, 4, 6 and 8 for mouse SCLC cell lines or on days 0, 2, 4 and 6 for the human SCLC cell line NJH29.</s><s>The absorbance wavelength was 570 nm with a reference wavelength of 650 nm.</s><s>EdU incorporation assay.</s><s>Transfected cells were treated with 10 mM EdU (5ethynyl-29-deoxyuridine) (Life Technologies) for 3 h before trypsinization for FACS. 1 3 10 5 live, GFP 1 cells were sorted and labelled with EdU using the Click-iT EdU Pacific Blue flow cytometry assay kit (Life Technologies).</s><s>Cells were then run through the BD FACSAria to analyse for per cent EdU incorporation.</s><s>Data reporting.</s><s>No statistical methods were used to predetermine sample size.</s></p><p><s>Extended Data Figure <ref type="figure" target="#fig_2">3</ref> | Genomic characterization of SCLC tumours.</s><s>a, Purity and ploidy determined in SCLC tumours by whole-genome sequencing presented as dot density plots showing median and the interquartile range (IQR) b, Subclonal architecture of SCLC in comparison to lung adenocarcinoma (AD).</s><s>Whole-genome sequencing data of SCLC and of adenocarcinoma (n 5 15) <ref type="bibr" target="#b6">11</ref> was analysed for the presence of subclonal populations using clustering of the derived cancer cell fraction (CCF) of all single nucleotide mutations.</s><s>To compare the emerging subclonal structure, we derived a subclonality score that takes into account the CCF of each subpopulation as well as its mutational burden (see Methods).</s><s>In order to prevent the low sequencing coverage (353 for SCLC and 633 for AD) from causing a systematic underrepresentation of the subclonal diversity in the mutation calls, we computed the contribution of a single read to the CCF on genome-wide average.</s><s>After systematically determining a threshold within the average increase of CCF per read values (see Methods for details), we determined the group of samples for which a reliable estimation of the subclonality score is not possible (grey area).</s><s>The subclonality scores of the remaining SCLC cases were then compared to those of the adenocarcinoma cases (P 5 0.000232; Mann-Whitney test).</s><s>c, Schematic representation of candidate genes with significant clustering of mutations in respective protein domains.</s><s>Somatic mutations and genomic translocations are mapped to the respective protein regions.</s><s>Hotspot mutations are highlighted in red.</s><s>d, e, Genomic alterations in the RB1 family proteins p107 (RBL1) and p130 (RBL2) (d), and in KIT and PIK3CA (e).</s><s>Somatic mutations in therapeutic target genes are listed and mapped to the protein domains of KIT and PIK3CA.</s><s>Mutations with potential therapeutic implications are highlighted in red.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>FPKMFigure 2 |</head><label>2</label><figDesc><div><p><s>Figure 2 | Universal bi-allelic inactivation of TP53 and RB1 in human SCLC.</s><s>a, Alterations of TP53 and RB1 were determined based on wholegenome sequencing data of 108 SCLC cases.</s><s>Samples are plotted from left to right.</s><s>Alleles A and B are represented for each case and colour-coded according to the somatic alteration.</s><s>The integral copy number (iCN) state of each allele is plotted; hemizygous losses are annotated as loss of heterozygosity (LOH), copy-neutral LOH or LOH at higher ploidy.</s><s>Samples retaining allele A and B show alterations on both alleles (bi-allelic alterations).</s><s>b, Circos plot of case S02297 showing intra-and interchromosomal translocations between chromosome 3 and 11.</s><s>The copy number state of the respective chromosomal regions (iCN) is plotted as a heatmap.</s><s>The genomic context of CCND1 (on chromosome 11) is highlighted.</s><s>c, Significantly differentially expressed genes encoded on chromosome 11 are analysed in both chromothripsis cases in comparison to all other tumours.</s><s>Positive and negative z-scores show upregulation and downregulation of genes, respectively (P , 0.05; *q-value ,0.05).</s><s>d, Distribution of CCND1 expression over 81 SCLC samples.</s><s>Chromothripsis cases are highlighted in red.</s><s>e, Haematoxylin and eosin (H&amp;E) and immunohistochemistry staining for cyclin D1 and Rb1 for sample S02297.</s><s>Original magnification, 3400.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 3 |</head><label>3</label><figDesc><div><p><s>Figure3| Recurrent rearrangements generating oncogenic variants of TP73.</s><s>a, Genomic breakpoints identified by whole-genome sequencing were mapped to their chromosomal locations.</s><s>Recurrent breakpoints (n .</s><s>6 samples) are highlighted in colours.</s><s>b, Schematic representation of the TP73 locus (hg19) illustrating intragenic translocations.</s><s>Coding and non-coding regions of the annotated exons are shown as black and white boxes, respectively.</s><s>c, Schematic representation of exons encoding p73, p73Dex2, p73Dex2/3 and p73Dex10.</s><s>d, Exon skipping events were assessed in the transcriptome data of samples with genomic translocations resulting in p73Dex2, p73Dex2/3 and p73Dex10 transcript variants.</s><s>S02139 served as a reference sample without TP73 alterations.</s><s>The expression of uncommon exon combinations is highlighted in red.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 4 |Figure 5 |</head><label>45</label><figDesc><div><p><s>Figure 4 | Notch is a tumour suppressor and a key regulator of neuroendocrine differentiation in SCLC.</s><s>a, Unsupervised expression analysis of human SCLC tumours.</s><s>Tumour samples are arranged in columns and grouped by the expression of differentially expressed genes (rows).</s><s>Expression values are represented as a heatmap; yellow and blue indicate high and low expression, respectively.</s><s>b, Schematic representation of NOTCH1 and NOTCH2.</s><s>Somatic mutations are mapped to the respective protein domains.</s><s>Damaging and missense mutations are highlighted in red and black, respectively.</s><s>c, Representative H&amp;E images of lungs from Trp53;Rb1;Rbl2 triple-knockout (TKO) or TKO;N2ICD (Notch2) mice collected 3 months after Ad-Cre instillation.</s><s>Scale bar, 1 mm.</s><s>Tumours were quantified for each genotype (n 5 8).</s><s>Statistical significance was determined by two-tailed unpaired Student's t-test.</s><s>d, Survival analysis of TKO (n 5 7, median survival 5 210 days) and TKO;N2ICD (n 5 8, median survival 5 274 days) mice.</s><s>Statistical significance was determined by log-rank test.</s><s>e, Cell viability assay of the murine SCLC cell line KP1 transfected with a N1ICD (Notch1) expression plasmid or empty vector control (Ctrl) (3 independent biological replicas with 3 technical replicas each).</s><s>Fold growth is normalized to day 0; representative images were taken on day 8. Scale bar, 50 mm.</s><s>Statistical significance was determined by two-tailed paired Student's t-test.</s><s>f, Mouse SCLC cells were transfected with control or N1ICD and analysed 48 h after transfection by gene expression microarrays.</s><s>The heatmap describes differentially expressed genes in control or N1ICD-transfected cells (n 5 3, each); red and green indicate high and low expression, respectively.</s><s>*P , 0.05; **P , 0.01; ***P , 0.001.</s><s>Data are represented as mean 6 s.d.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><head></head><label></label><figDesc><div><p></p></div></figDesc><graphic coords="12,57.60,57.77,474.41,346.45" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><head></head><label></label><figDesc><div><p></p></div></figDesc><graphic coords="15,43.82,57.77,513.30,293.10" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><head></head><label></label><figDesc><div><p></p></div></figDesc><graphic coords="18,88.67,57.77,412.21,449.63" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><head></head><label></label><figDesc><div><p></p></div></figDesc><graphic coords="21,45.58,57.77,509.78,414.14" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head></head><label></label><figDesc><div><p><s>Received 15 January; accepted 15 June 2015.</s></p></div></figDesc><table><row><cell>Published online 13 July 2015.</cell></row></table><note><p><s>1.vanMeerbeeck, J. P., Fennell, D. A. &amp; De Ruysscher, D. K. Small-cell lung cancer.</s><s>Lancet 378, 1741-1755 (2011).</s><s>2. Peifer, M. et al.</s><s>Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer.</s><s>Nature Genet.</s><s>44, 1104-1110 (2012).</s><s>3. Rudin, C. M. et al.</s><s>Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer.</s><s>Nature Genet.</s><s>44, 1111-1116 (2012).</s><s>4. Takahashi, T. et al. p53: a frequent target for genetic abnormalities in lung cancer.</s><s>Science 246, 491-494 (1989).</s></p></note></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Acknowledgements We are grateful to all the patients who contributed their tumour specimens.</s><s>We thank the computing center of the University of Cologne (RRZK) for providing the CPU time on the DFG-funded supercomputer 'CHEOPS', as well as for the support.</s><s>We thank S. Artavanis-Tsakonas and S. Fre for the gift of the mice with inducible NICD expression.</s><s>We thank C. Nguyen, J. Berg, J. Heuckmann, F. Malchers, C. Lovely and A. Bernschein for scientific discussions and advice.</s><s>We thank Genentech/ gRED for providing raw sequencing data from a previously published study 3 .</s><s>Some tumors in these studies were provided by the LungBiobank Heidelberg, member of the NCT-Tissue bank, the biomaterial bank Heidelberg and the biobank platform of the German Center for Lung Research, Heidelberg, Germany.</s><s>This work was supported by the German Cancer Aid (Deutsche Krebshilfe) as part of the small cell lung cancer genome sequencing consortium (grant ID: 109679 to R.K.T., M.P., R.B., P.N., M.V. and S.A.H.).</s><s>Further support was provided by the Korea Research Foundation (KRF 2011-0030105; grant to S.J.J.).</s><s>Additional funding was provided by the NIH</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Supplementary Information is available in the online version of the paper.</s><s>The copy number (CN) states were computed from SNP array (SNP 6.0) and from whole-genome sequencing (WGS) data.</s><s>The samples are sorted according to their amplitude of deletions or amplifications.</s><s>e, Amplifications of IRS2 were determined by FISH analysis.</s><s>IRS amplifications were quantified based on the ratio of red signals (IRS2-specific probe) to green signals (centromere probe for chromosome 13).</s><s>Lymphocyte spreads and SCLC tumours without detectable IRS2 amplifications served as negative controls.</s><s>Scale bar, 100 mm.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Extended Data</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Extended Data</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ARTICLE RESEARCH</head><p><s>G2015 Macmillan Publishers Limited.</s><s>All rights reserved</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Molecular genetics of small cell lung carcinoma</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">I</forename><surname>Wistuba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">F</forename><surname>Gazdar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Minna</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Semin. Oncol</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="3" to="13" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Horowitz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc. Natl Acad. Sci. USA</title>
		<imprint>
			<biblScope unit="volume">87</biblScope>
			<biblScope unit="page" from="2775" to="2779" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Variable mutations of the RB gene in small-cell lung carcinoma</title>
		<author>
			<persName><forename type="first">N</forename><surname>Mori</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncogene</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="1713" to="1717" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model</title>
		<author>
			<persName><forename type="first">R</forename><surname>Meuwissen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Cell</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="181" to="189" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Loss of p130 accelerates tumor development in a mouse model for human small-cell lung carcinoma</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">E</forename><surname>Schaffer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="page" from="3877" to="3883" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Mcfadden</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">156</biblScope>
			<biblScope unit="page" from="1298" to="1311" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing</title>
		<author>
			<persName><forename type="first">M</forename><surname>Imielinski</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">150</biblScope>
			<biblScope unit="page" from="1107" to="1120" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing</title>
		<author>
			<persName><forename type="first">J</forename><surname>Zhang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">346</biblScope>
			<biblScope unit="page" from="256" to="259" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Spatial and temporal diversity in genomic instability processes defines lung cancer evolution</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">C</forename><surname>De Bruin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">346</biblScope>
			<biblScope unit="page" from="251" to="256" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">A census of human cancer genes</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Futreal</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature Rev. Cancer</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="177" to="183" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">COSMIC: exploring the world&apos;s knowledge of somatic mutations in human cancer</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Forbes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nucleic Acids Res</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="D805" to="D811" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Mutational heterogeneity in cancer and the search for new cancer-associated genes</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Lawrence</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">499</biblScope>
			<biblScope unit="page" from="214" to="218" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers</title>
		<author>
			<persName><forename type="first">A</forename><surname>Yokomizo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncogene</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="475" to="479" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond</title>
		<author>
			<persName><forename type="first">M</forename><surname>Holderfield</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Deuker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Mccormick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mcmahon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature Rev. Cancer</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="455" to="467" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer</title>
		<author>
			<persName><forename type="first">K</forename><surname>Hibi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncogene</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="2291" to="2296" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors</title>
		<author>
			<persName><forename type="first">S</forename><surname>Hirota</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">279</biblScope>
			<biblScope unit="page" from="577" to="580" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Oncogenic mutation of PIK3CA in small cell lung carcinoma: a potential therapeutic target pathway for chemotherapy-resistant lung cancer</title>
		<author>
			<persName><forename type="first">T</forename><surname>Shibata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kokubu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Tsuta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hirohashi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Lett</title>
		<imprint>
			<biblScope unit="volume">283</biblScope>
			<biblScope unit="page" from="203" to="211" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Analysis of a new homozygous deletion in the tumor suppressor region at 3p12.3 reveals two novel intronic noncoding RNA genes</title>
		<author>
			<persName><forename type="first">D</forename><surname>Angeloni</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Genes Chromosom. Cancer</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="676" to="691" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Molecular alterations to human chromosome 3p loci in neuroendocrine lung tumors</title>
		<author>
			<persName><forename type="first">A</forename><surname>Kovatich</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">83</biblScope>
			<biblScope unit="page" from="1109" to="1117" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer</title>
		<author>
			<persName><forename type="first">J</forename><surname>Weiss</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Sci. Transl. Med</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="62" to="93" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Criteria for inference of chromothripsis in cancer genomes</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">O</forename><surname>Korbel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Campbell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">152</biblScope>
			<biblScope unit="page" from="1226" to="1236" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Two genetic hits (more or less) to cancer. 1</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Knudson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature Rev. Genet</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="157" to="162" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">A continuum model for tumour suppression</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">H</forename><surname>Berger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Knudson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">P</forename><surname>Pandolfi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">476</biblScope>
			<biblScope unit="page" from="163" to="169" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">The P16/cyclin D1/Rb pathway in neuroendocrine tumors of the lung</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Beasley</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hum. Pathol</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="136" to="142" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Northcott</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">511</biblScope>
			<biblScope unit="page" from="428" to="434" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Comprehensive molecular characterization of human colon and rectal cancer</title>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">487</biblScope>
			<biblScope unit="page" from="330" to="337" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note>The Cancer Genome Atlas Network</note>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Frequent L1 retrotranspositions originating from TTC28 in colorectal cancer</title>
		<author>
			<persName><forename type="first">E</forename><surname>Pitka ¨nen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Cajuso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Katainen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Kaasinen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Va ¨lima ¨ki</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncotarget</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="853" to="859" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Somatic retrotransposition in human cancer revealed by whole-genome and exome sequencing</title>
		<author>
			<persName><forename type="first">E</forename><surname>Helman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Lawrence</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Stewart</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Genome Res</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="1053" to="1063" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">The role of the TP73 gene and its transcripts in neuro-oncology</title>
		<author>
			<persName><forename type="first">R</forename><surname>Jancalek</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br. J. Neurosurg</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="598" to="605" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Autonomous growth and hepatocarcinogenesis in transgenic mice expressing the p53 family inhibitor DNp73</title>
		<author>
			<persName><forename type="first">A</forename><surname>Tannapfel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Carcinogenesis</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="211" to="218" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">IAPP-driven metabolic reprogramming induces regression of p53-deficient tumours in vivo</title>
		<author>
			<persName><forename type="first">A</forename><surname>Venkatanarayan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">517</biblScope>
			<biblScope unit="page" from="626" to="630" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Possible roles of DLK1 in the Notch pathway during development and disease</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">A</forename><surname>Falix</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Aronson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Lamers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">C</forename><surname>Gaemers</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochim. Biophys. Acta</title>
		<imprint>
			<biblScope unit="volume">1822</biblScope>
			<biblScope unit="page" from="988" to="995" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Achaete-scute homolog-1 and Notch in lung neuroendocrine development and cancer</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Ball</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Lett</title>
		<imprint>
			<biblScope unit="volume">204</biblScope>
			<biblScope unit="page" from="159" to="169" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers</title>
		<author>
			<persName><forename type="first">A</forename><surname>Augustyn</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc. Natl Acad. Sci. USA</title>
		<imprint>
			<biblScope unit="volume">111</biblScope>
			<biblScope unit="page" from="14788" to="14793" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<monogr>
		<title level="m" type="main">Notch signaling induces cell cycle arrest in small cell lung cancer cells Cancer Res</title>
		<author>
			<persName><forename type="first">V</forename><surname>Sriuranpong</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2001">2001</date>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="3200" to="3205" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Notch1 signaling controls cell proliferation, apoptosis and differentiation in lung carcinoma</title>
		<author>
			<persName><forename type="first">H</forename><surname>Wael</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lung Cancer</title>
		<imprint>
			<biblScope unit="volume">85</biblScope>
			<biblScope unit="page" from="131" to="140" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation</title>
		<author>
			<persName><forename type="first">A</forename><surname>Rangarajan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">EMBO J</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="3427" to="3436" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">01ZX1406 to M.P.), by the Deutsche Forschungsgemeinschaft (DFG; through TH1386/3-1 to R.K.T and KFO-286 to P.N.), by the German federal state North Rhine Westphalia (NRW), by the European Union (European Regional Development Fund: Investing In Your Future) as part of the PerMed NRW initiative (grant 005-1111-0025 to</title>
		<author>
			<persName><forename type="first">R</forename><surname>Qi</surname></persName>
		</author>
		<idno>5R01CA114102-08 to J.S</idno>
	</analytic>
	<monogr>
		<title level="m">the German Ministry of Science and Education (BMBF) as part of the NGFNplus program</title>
				<editor>
			<persName><forename type="first">T</forename><forename type="middle">K</forename></persName>
		</editor>
		<editor>
			<persName><forename type="first">J</forename><forename type="middle">Y</forename></persName>
		</editor>
		<editor>
			<persName><forename type="first">R</forename><forename type="middle">I</forename></persName>
		</editor>
		<meeting><address><addrLine>NCC Biobank</addrLine></address></meeting>
		<imprint>
			<date type="published" when="2003">2003</date>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="23A" to="24" />
		</imprint>
	</monogr>
	<note>), by the Roy Castle Lung Cancer Foundation UK. to J.K.F.), by the AIRC/MGAF grant 12983 (to L.A.M.) and by A*STAR in Singapore (scholarship to J.S.L.). J.S. is the Harriet and Mary Zelencik Scientist in Children&apos;s Cancer and Blood Diseases</note>
</biblStruct>

<biblStruct xml:id="b38">
	<monogr>
		<title level="m" type="main">Bos performed data analysis</title>
		<author>
			<persName><forename type="first">Author</forename><surname>Contributions</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S L</forename></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K T ; J G</forename></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S L</forename></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">L</forename></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Pu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">¨</forename></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S W</forename></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">O K</forename></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">B</forename></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">S J G</forename><surname>Designed Experiments</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S L</forename></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">D</forename></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">T</forename></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename></persName>
		</author>
		<author>
			<persName><forename type="first">S.-M</forename><forename type="middle">C</forename></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">K</forename></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">V</forename></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Pi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">S</forename></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">B</forename></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M S</forename></persName>
		</author>
		<author>
			<persName><forename type="first">M. ; J</forename><forename type="middle">G</forename></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S L</forename></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A H</forename></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">V</forename></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S W</forename></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">O K</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">C</forename></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">L</forename></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">V</forename></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">H</forename></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E B</forename></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">D T</forename></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">H</forename></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">O</forename></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J J</forename></persName>
		</author>
		<author>
			<persName><forename type="first">G.K ; P</forename><forename type="middle">P M</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">Z</forename></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M W</forename></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A R</forename></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">S</forename></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">K</forename></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A M</forename></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L T</forename></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K F</forename></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">C</forename></persName>
		</author>
		<author>
			<persName><forename type="first">.-V</forename></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">R</forename></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">P</forename></persName>
		</author>
		<author>
			<persName><forename type="first">O.-T</forename><forename type="middle">B</forename></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename></persName>
		</author>
		<author>
			<persName><forename type="first">.-I</forename></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">T</forename><surname>Ko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">¨</forename></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sc</surname></persName>
		</author>
		<editor>J.B., M.Sa, M.S.-C., H.B.S., Y.Y., S.P., L.H., R.B. and E.B.</editor>
		<imprint/>
	</monogr>
	<note>Bog performed experiments. contributed with murine and human tissue samples</note>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Microarray data on mouse cell lines is accessible through Gene Expression Omnibus (GEO) accession number GSE69091. Reprints and permissions information is available at www.nature.com/reprints. The authors declare competing financial interests: details are available in the online version of the paper. Readers are welcome to comment on the online version of the paper. Correspondence and requests for materials should be addressed to</title>
		<idno type="DOI">10.1038/nature14664</idno>
		<ptr target="http://www.translational-genomics.uni-koeln.de/scientific-resources/" />
	</analytic>
	<monogr>
		<title level="m">Author Information Affymetrix SNP 6.0, whole-genome, and transcriptome sequencing on human specimen have been deposited at the European Genome-phenome Archive under the accession code EGAS00001000925</title>
				<editor>
			<persName><forename type="first">R</forename><forename type="middle">K T</forename></persName>
		</editor>
		<editor>
			<persName><forename type="first">)</forename></persName>
		</editor>
		<editor>
			<persName><forename type="first">J</forename><forename type="middle">S</forename></persName>
		</editor>
		<imprint/>
	</monogr>
	<note>Whole-exome and whole-genome sequencing data of murine SCLC tumors can be accessed through. julsage@stanford.edu) or M.P. (mpeifer@uni-koeln.de</note>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Marc Bos 1 , Sebastian Michels 13 , Ignacija Vlasic 14 , Danila Seidel 1 , Berit Pinther 1 , Philipp Schaub 1 , Christian Becker 15</title>
	</analytic>
	<monogr>
		<title level="m">Sung-Min Chun 3 , Deokhoon Kim 9</title>
		<title level="s">Lucia A. Muscarella</title>
		<editor>
			<persName><forename type="first">Yong-Hee</forename><surname>Kim 27</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">Pierre</forename><forename type="middle">P</forename><surname>Massion</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">Yong</forename><surname>Zou 28</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">Dragana</forename><surname>Jovanovic 29</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">Milica</forename><surname>Kontic 29</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">Gavin</forename><forename type="middle">M</forename><surname>Wright 30</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">Prudence</forename><forename type="middle">A</forename><surname>Russell 31</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">Benjamin</forename><surname>Solomon 32</surname></persName>
		</editor>
		<meeting><address><addrLine>Angela Torres 2 , Maia Segura Wang 7; Matt Wilkerson 10 , Neil Hayes; Berlin, Germany</addrLine></address></meeting>
		<imprint>
			<date>Jan O. Korbel 7. Jun Yokota 17. Koji Tsuta 19. Hans Hoffmann 21. Martin Schuler 45. 20133</date>
			<biblScope unit="volume">8</biblScope>
		</imprint>
	</monogr>
	<note>Thomas Zander. Sascha Anse ´n13 , Michael Hallek 13,55 , Ju ¨rgen Wolf 13 , Martin Vingron 56 , Yasushi Yatabe 57 , William D. Travis 58. Peter Nu ¨rnberg 15,55,59 , Christian Reinhardt 14 , Sven Perner 9. 39 Tumor Genomics Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS -Istituto Nazionale Tumori</note>
</biblStruct>

<biblStruct xml:id="b41">
	<monogr>
		<title level="m" type="main">41 Institute of Clinical Medicine, Faculty of Medicine</title>
		<author>
			<persName><forename type="first">Italy</forename><surname>Milan</surname></persName>
		</author>
		<imprint>
			<date>20133</date>
			<biblScope unit="page">44</biblScope>
			<pubPlace>Milan, Italy; Norway</pubPlace>
		</imprint>
		<respStmt>
			<orgName>40 Thoracic Surgery Unit, Department of Surgery, Fondazione IRCCS Istituto Nazionale Tumori ; University of Oslo, N-0424 Oslo, Norway. 42 Department of Oncology, Norwegian Radium Hospital, Oslo University Hospital, N-0310 Oslo, Norway. 43 Department of Pathology, Norwegian Radium Hospital, Oslo University Hospital, N-0310 Oslo</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<monogr>
		<title level="m" type="main">The Netherlands. 45 West German Cancer Center</title>
		<imprint>
			<biblScope unit="page">69120</biblScope>
			<pubPlace>Essen, Germany</pubPlace>
		</imprint>
		<respStmt>
			<orgName>Department of Pathology ; VU University Medical Center, 1007 MB Amsterdam ; Department of Medical Oncology, University Hospital Essen</orgName>
		</respStmt>
	</monogr>
	<note>46 German Cancer Consortium (DKTK</note>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">47 Departments of Immunology</title>
		<author>
			<persName><forename type="first">Germany</forename><surname>Heidelberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Genetics and Pathology, and Medical Sciences</title>
		<imprint>
			<biblScope unit="page">75185</biblScope>
		</imprint>
	</monogr>
	<note>Respiratory, Allergy and Sleep Research</note>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">49 Department of Clinical Science</title>
		<author>
			<persName><forename type="first">Sweden</forename><surname>Uppsala</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), 08908 Hospitalet de Llobregat</title>
				<meeting><address><addrLine>Barcelona, Spain; Bergen, Norway. 51 Computing Center; Cologne, Germany</addrLine></address></meeting>
		<imprint>
			<biblScope unit="page">50931</biblScope>
		</imprint>
		<respStmt>
			<orgName>Center for Cancer Biomarkers, University of Bergen, N-5058 Bergen, Norway. 50 Department of Gynecology and Obstetrics, Haukeland University Hospital ; University of Cologne ; 52 Department of Informatics, University of Cologne, 50931 Cologne, Germany. 53 Institute of Legal Medicine, University of Cologne</orgName>
		</respStmt>
	</monogr>
	<note>48 Genes and Cancer Group</note>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">University of Cologne, 50931 Cologne, Germany. 56 Computational Molecular Biology Group, Max Planck Institute for Molecular Genetics</title>
		<author>
			<persName><forename type="first">Germany</forename><surname>Cologne</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Institute Albert Bonniot</title>
		<imprint>
			<biblScope unit="volume">38043</biblScope>
			<biblScope unit="page">69008</biblScope>
			<date>14195</date>
		</imprint>
		<respStmt>
			<orgName>54 Gastrointestinal Cancer Group Cologne, Center of Integrated Oncology Cologne-Bonn, Department I for Internal Medicine, University Hospital of Cologne ; University of Cologne ; CHU Grenoble INSERM U823, University Joseph Fourier</orgName>
		</respStmt>
	</monogr>
	<note>Aichi Cancer Center. {Present address: Genetic Cancer Susceptibility Group, Section of Genetics, International Agency for Research on Cancer (IARC-WHO</note>
</biblStruct>

<biblStruct xml:id="b46">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">France</forename><surname>Lyon</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Genome-wide identification of genes with amplification and/or fusion in small cell lung cancer</title>
		<author>
			<persName><forename type="first">R</forename><surname>Iwakawa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Genes Chromosomes Cancer</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page" from="802" to="816" />
			<date type="published" when="2013">2013</date>
			<publisher>Macmillan Publishers Limited</publisher>
		</imprint>
	</monogr>
	<note>All rights reserved 43</note>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">A genomics-based classification of human lung tumors</title>
		<author>
			<persName><forename type="first">D</forename><surname>Seidel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Sci. Transl. Med</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="209" to="153" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Notch3 marks clonogenic mammary luminal progenitor cells in vivo</title>
		<author>
			<persName><forename type="first">D</forename><surname>Lafkas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Cell Biol</title>
		<imprint>
			<biblScope unit="volume">203</biblScope>
			<biblScope unit="page" from="47" to="56" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">A global doublefluorescent Cre reporter mouse</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Muzumdar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Tasic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Miyamichi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Luo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Genesis</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="593" to="605" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">CGARS: cancer genome analysis by rank sums</title>
		<author>
			<persName><forename type="first">X</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Thomas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Peifer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bioinformatics</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="1295" to="1296" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Fast and accurate short read alignment with Burrows-Wheeler transform</title>
		<author>
			<persName><forename type="first">H</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Durbin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bioinformatics</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="1754" to="1760" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids</title>
		<author>
			<persName><forename type="first">L</forename><surname>Fernandez-Cuesta</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Commun</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page">3518</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">S</forename><surname>Jahchan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Discov</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="1364" to="1377" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
